Skip to main content
Evidence Snapshot

Beta-2 adrenergic receptor

CHEMBL3373 SINGLE PROTEIN Bos taurus
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T15:01:48Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL3373
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Beta-2 adrenergic receptor as ChEMBL target CHEMBL3373, mapped to UniProt Q28044. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Beta-2 adrenergic receptor
SINGLE PROTEIN · Bos taurus
As of 2026-09-13
ChEMBL target ID
CHEMBL3373
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
Q28044
Beta-2 adrenergic receptor
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Beta-2 adrenergic receptor matters

As of 2026-09-13

Beta-2 adrenergic receptor is reviewed as Beta-2 adrenergic receptor (UniProt Q28044); the current evidence base includes 11 approved drugs, 69 compounds, and 18 assays, with lead potency reaching pChEMBL 9.4.

Disease context
Disease signal

Disease relevance is not yet populated for this evidence card.

This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Activity base
Portfolio and assay base

ChEMBL currently tracks 11 approved drugs, 69 compounds, and 18 assays for this target. The dominant activity type is KD. CHEMBL1159892 is the current potency anchor at pChEMBL 9.4.

Use CHEMBL1159892 as the tractability anchor when discussing potency (pChEMBL 9.4).

Activity source · ChEMBL 36 via Core Engine
11 approved pChEMBL 9.4
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Beta-2 adrenergic receptor matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt Q28044, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

69
Total Compounds
18
Total Assays
11
Approved Drugs
IC50: 9.0, KI: 28.0, KD: 34.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL1159892
 9.4 Kd Clinical
No preferred name
CHEMBL1159723
 9.2 Kd —
No preferred name
CHEMBL1671
 9.1 Kd Approved
No preferred name
CHEMBL266195
 8.5 IC50 Clinical
No preferred name
CHEMBL1159714
 8.0 Kd —

Approved Drugs

Structure Compound First Approval
SOTALOL
CHEMBL471
 1992
BETAXOLOL
CHEMBL423
 1985
ALBUTEROL
CHEMBL714
 1981
PROPRANOLOL HYDROCHLORIDE
CHEMBL1671
 1967
ISOPROTERENOL
CHEMBL434
 1956
PRONETALOL
CHEMBL16476
 —
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T15:01:48Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL3373